Soluble aggregates of the amyloid-β peptide are trapped by serum albumin to enhance amyloid-β activation of endothelial cells

Abstract

Background: Self-assembly of the amyloid-β peptide (Aβ) has been implicated in the pathogenesis of Alzheimer's disease (AD). As a result, synthetic molecules capable of inhibiting Aβ self-assembly could serve as therapeutic agents and endogenous molecules that modulate Aβ self-assembly may influence disease progression. However, increasing evidence implicating a principal pathogenic role for small soluble Aβ aggregates warns that inhibition at intermediate stages of Aβ self-assembly may prove detrimental. Here, we explore the inhibition of Aβ1-40 self-assembly by serum albumin, the most abundant plasma protein, and the influence of this inhibition on Aβ1-40 activation of endothelial cells for monocyte adhesion. Results: It is demonstrated that serum albumin is capable of inhibiting in a dose-dependent manner both the formation of Aβ1-40 aggregates from monomeric peptide and the ongoing growth of Aβ1-40 fibrils. Inhibition of fibrillar Aβ1-40 aggregate growth is observed at substoichiometric concentrations, suggesting that serum albumin recognizes aggregated forms of the peptide to prevent monomer addition. Inhibition of Aβ1-40 monomer aggregation is observed down to stoichiometric ratios with partial inhibition leading to an increase in the population of small soluble aggregates. Such partial inhibition of Aβ1-40 aggregation leads to an increase in the ability of resulting aggregates to activate endothelial cells for adhesion of monocytes. In contrast, Aβ1-40 activation of endothelial cells for monocyte adhesion is reduced when more complete inhibition is observed. Conclusion: These results demonstrate that inhibitors of Aβ self-assembly have the potential to trap small soluble aggregates resulting in an elevation rather than a reduction of cellular responses. These findings provide further support that small soluble aggregates possess high levels of physiological activity and underscore the importance of resolving the effect of Aβ aggregation inhibitors on aggregate size. © 2009 Barcelo et al; licensee BioMed Central Ltd.